RAPT Therapeutics receives Nasdaq bid price deficiency notice; plans reverse stock split

RAPT Therapeutics, Inc.

Received Nasdaq notice on May 21, 2025: average closing bid price below $1.00 for 30 consecutive days.
Has 180 days (until November 17, 2025) to cure by closing at $1.00 for 10 consecutive business days.
Board approved 1-for-8 reverse stock split; stockholders vote on May 29, 2025 annual meeting.
If not cured, may transfer to Nasdaq Capital Market or face delisting; appeal to Panel possible.

item 3.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.